Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype

James Chodosh, Virgil P. Holder, Yan Jun Gan, Asim Belgaumi, Jeffery Sample, John W. Sixbey

Research output: Contribution to journalArticle

80 Scopus citations

Abstract

The hallmark of infection by human herpesviruses, life-long persistence in the host, is unaffected by current antiviral therapies effective against replication of virus. In vitro studies indicated that low concentrations of the ribonucleotide reductase inhibitor, hydroxyurea, completely eliminated Epstein-Barr virus (EBV) episomes from latently infected Burkitt's lymphoma (BL) cell subsets, providing the first example of chemotherapeutic eradication of a latent herpesvirus from any cell population. Unlike parental EBV-positive BL cells, virus-free cell progeny from one treated cell line no longer exhibited the malignant phenotype in tumorigenicity assays. Hydroxyurea-treated primary B lymphocytes immortalized by EBV ceased to proliferate as episomes were lost. The altered growth phenotype of both BL cells and immortalized primary B cells suggests that latent EBV is an appropriate and accessible therapeutic target for treatment of some EBV- induced lymphoproliferations.

Original languageEnglish (US)
Pages (from-to)1194-1201
Number of pages8
JournalJournal of Infectious Diseases
Volume177
Issue number5
DOIs
StatePublished - Jan 1 1998

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype'. Together they form a unique fingerprint.

  • Cite this